Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nikovari Bio Tech
San Francisco, California, United Statesnikovari.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nikovari is a pre-clinical stage biotechnology company focused on developing next-generation gene regulation therapies for difficult-to-treat cancers. The company utilizes a proprietary platform designed to achieve precise control over gene expression, specifically targeting oncogenic drivers like KRAS that have historically been challenging to inhibit effectively. By combining advanced molecular biology with computational design, Nikovari aims to create highly selective therapeutics that minimize off-target effects while maximizing anti-tumor activity. Their lead programs are currently focused on solid tumors with high unmet medical needs.
- Therapeutic areas
- Oncology
- Modalities
- Gene therapySmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Nikovari Bio Tech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nikovari Bio Tech.